bupivacaine hydrochloride; epinephrine bitartrate
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE (bupivacaine hydrochloride; epinephrine bitartrate) by Pfizer is impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. Approved for regional anesthesia, analgesia for surgery, dental and 4 more indications. First approved in 1983.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
Bupivacaine hydrochloride with epinephrine bitartrate is a long-acting local anesthetic injectable used for regional anesthesia and analgesia during surgical, dental, obstetrical, and diagnostic procedures. It works by blocking nerve impulse generation and conduction, with epinephrine serving as a vasoconstrictor to slow systemic absorption and prolong anesthetic effect. The combination provides onset within 2-10 minutes with duration up to 7 hours.
As LOE approaches, career opportunities will shift from growth-focused roles toward lifecycle management, generic transition planning, and cost optimization initiatives.
impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction…
Worked on BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on bupivacaine with epinephrine offers stable, specialized expertise in anesthetic pharmacology and regional procedure markets, but limited career growth potential due to LOE status. Professionals should expect focus on defensive strategy, generic transition, cost optimization, and supply chain resilience rather than market expansion or innovation initiatives.